United States securities and exchange commission logo





                             August 31, 2021

       Mai-Britt Zocca, Ph.D.
       Chief Executive Officer
       IO Biotech, Inc.
       Ole Maal  es Vej 3
       DK-2200 Copenhagen N
       Denmark

                                                        Re: IO Biotech, Inc.
                                                            Amendment No. 1 to
Draft Registration Statement on Form S-1
                                                            Submitted August 9,
2021
                                                            CIK No. 0001865494

       Dear Dr. Zocca:

             We have reviewed your amended draft registration statement and
have the following
       comments. In some of our comments, we may ask you to provide us with
information so we
       may better understand your disclosure.

              Please respond to this letter by providing the requested
information and either submitting
       an amended draft registration statement or publicly filing your
registration statement on
       EDGAR. If you do not believe our comments apply to your facts and
circumstances or do not
       believe an amendment is appropriate, please tell us why in your
response.

             After reviewing the information you provide in response to these
comments and your
       amended draft registration statement or filed registration statement, we
may have additional
       comments.

       Amendment No. 1 to Draft Registration Statement on Form S-1 submitted
August 9, 2021

       Overview, page 1

   1.                                                   We note your revisions
in response to prior comment 1 and reissue the comment in part. It
                                                        remains unclear whether
the results/observations in your a single-arm Phase 1/2 clinical
                                                        trial of 30 patients
are statistically significant. Also, it does not appear that you have
                                                        addressed the final
sentence of the prior comment by telling us whether you were able to
                                                        evaluate and determine
the contributions of IO102-IO103 as compared to those of the
                                                        combination therapy.
Please revise or advise.
 Mai-Britt Zocca, Ph.D.
FirstName
IO Biotech,LastNameMai-Britt   Zocca, Ph.D.
            Inc.
Comapany
August 31, NameIO
           2021     Biotech, Inc.
August
Page 2 31, 2021 Page 2
FirstName LastName
        You may contact Al Pavot at (202) 551-3738 if you have questions
regarding comments
on the financial statements and related matters. Please contact Joe McCann at
(202) 551-6262
with any other questions.



                                                         Sincerely,

                                                         Division of
Corporation Finance
                                                         Office of Life
Sciences
cc:      Frank Rahmani, Esq.